NeueHealth — Q4 2024 Earnings Presentation
10 slides from NeueHealth's earnings presentation, Mar 20, 2025
Slide 1: NeueHealth Fourth Quarter and Full Year 2024 Earnings Presentation
NeueHealth Fourth Quarter and Full Year 2024 - Earnings Presentation March 20, 2025 Privileged & Confidential | © 2025
Slide 2: Disclaimer
Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re
Slide 3: NeueHealth Delivered Strongest Financial Performance to Date in 2024
NeueHealth Delivered Strongest Financial Performance to Date in 2024 NeueHealth Value-driven care delivery and provider enablement business partnering with leading health plans, government programs, and medical groups to deliver high-quality, affordable care to all consumers 2024 Results: $936.7M $2
Slide 4: Overview of Q4 2024 Results for Continuing Operations
Overview of Q4 2024 Results for Continuing Operations Strong Q4 performance driven by continued momentum in NeueCare and NeueSolutions business segments Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Q4 ‘24 Revenue of $232.6, in-line
Slide 5: Overview of Full Year 2024 Results for Continuing Operations
Overview of Full Year 2024 Results for Continuing Operations Established solid foundation for driving long-term, sustainable growth in 2025 and beyond Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Revenue of $936.7 million for the f
Slide 6: Balance Sheet and Liquidity Highlights
Balance Sheet and Liquidity Highlights Building a strong foundation for long-term sustainable growth Summary Balance Sheet Q4’24 Key Considerations December 31, December 31, • $202.8 million in total cash and investments, including $109.6 million ($ in thousands) 2024 2023 in our regulated entities.
Slide 7: Appendix
Appendix
Slide 8: Non-GAAP Reconciliation: Adjusted EBITDA
Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended Years Ended December 31, December 31, December 31, December 31, ($ in thousands) 2024 2023 2024 2023 Net Loss $ 2,523 $ (460,572) $ (99,717) $ (1,265,808) Loss from discontinued operations (45,003) 397,745 (2,341) 638,066 EBITDA adjustments
Slide 9: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio
Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended Years Ended December 31, December 31, December 31, December 31, ($ in thousands) 2024 2023 2024 2023 GAAP Operating Cost Ratio 31.3% 22.3% 29.2% 24.7% Impact of share-based compensation expense (5.4)% (6.2)% (7.3)% (7.2)% Impa
Slide 10: Slide 10